Pacer Advisors
VRDN icon

Pacer Advisors’s Viridian Therapeutics VRDN Stock Holding History

Pacer Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-825
Closed -$10.7K – 2709
2024
Q2 		$10.7K Sell
825
-1,075
-57% -$14.9K ﹤0.01% 3537
2024
Q1 		$33.3K Buy
+1,900
New +$36.8K ﹤0.01% 3330

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Pacer Advisors's VRDN Position: Q3 2024 in Review

Pacer Advisors sold out of Viridian Therapeutics (VRDN) in Q3 2024, closing a stake of 825 shares — an estimated $10.7K sold.

Pacer Advisors first reported a position in VRDN in Q1 2024 and held it in 2 quarters. The position peaked at $33.3K in Q1 2024. 165 funds tracked by Wall St. Rank hold VRDN as of Q3 2024.

  • Pacer Advisors reported no remaining Viridian Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 825 Viridian Therapeutics shares in Q3 2024, an estimated $10.7K.
  • Pacer Advisors first reported a position in Viridian Therapeutics in Q1 2024 and held it in 2 quarters.
  • Pacer Advisors's Viridian Therapeutics position peaked at $33.3K in Q1 2024.
  • 165 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.